Business Context and Reporting Period
Company: Outlook Therapeutics, Inc. (OTLK)
Filing Type: Form 8-K (Current Report)
Date of Report: April 1, 2024
Reporting Period: Event date April 1, 2024; Compliance period March 14, 2024 to March 28, 2024.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance status.
Material Changes
The Company received a Compliance Notice from The Nasdaq Stock Market LLC confirming it has regained compliance with Nasdaq Listing Rule 5550(a)(2). This rule requires a minimum bid price of $1.00 per share. The Company's closing bid price remained at or above $1.00 per share from March 14, 2024, through March 28, 2024, resulting in the closure of the prior non-compliance matter.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks. The primary risk addressed was the potential delisting due to low stock price, which has been resolved as of the report date.
Investor Verification Checklist
- Verify the current trading price of OTLK to ensure continued compliance with the $1.00 minimum bid price requirement.
- Confirm the status of the stock on The Nasdaq Capital Market to ensure no further delisting warnings are active.
- Review recent 10-Q or 10-K filings for financial health metrics, as this 8-K does not provide them.